《美股业绩》辉瑞季绩胜预期兼上调业绩预测 股价升近4%
道指成分股,美国辉瑞药厂(Pfizer)(PFE.US)公布第二季度业绩。季度纯利34.26亿美元,按年跌32%。每股季度摊薄纯利61美仙,经调整後为78美仙,高於市场预期的66美仙。季度收入按年跌11%至118.01亿美元,高於市场的115亿美元预测。
公司上调全年每股经调整纯利预测,由介乎2.82至2.92美元,上调至介乎2.85至2.95美元。全年收入预测亦轻微上调至介乎486亿至506亿美元。辉瑞指,新冠疫情导致民众减少使用处方药及注射疫苗,收入因而减少约5亿美元。公司亦披露,研发中新冠疫苗在疫情期间售价为每剂19.95美元,疫情过後会回复至按价值定价水平。
辉瑞股价昨(28日)升3.9%,为升幅最大道指成分股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.